To determine whether glucocorticoids are involved in pancreas development, glucocorticoid treatment of rat pancreatic buds in vitro was combined with the analysis of transgenic mice lacking the glucocorticoid receptor (GR) in specific pancreatic cells. In vitro treatment of embryonic pancreata with dexamethasone, a glucocorticoid agonist, induced a decrease of insulin-expressing cell numbers and a doubling of acinar cell area, indicating that glucocorticoids favored acinar differentiation; in line with this, expression of Pdx-1, Pax-6, and Nkx6.1 was downregulated, whereas the mRNA levels of Ptf1-p48 and Hes-1 were increased. The selective inactivation of the GR gene in insulin-expressing ␤-cells in mice (using a RIP-Cre transgene) had no measurable consequences on ␤-or ␣-cell mass, whereas the absence of GR in the expression domain of Pdx-1 (Pdx-Cre transgene) led to a twofold increased ␤-cell mass, with increased islet numbers and size but normal ␣-cell mass in adults. These results demonstrate that glucocorticoids play an important role in pancreatic ␤-cell lineage, acting before hormone gene expression onset and possibly also modulating the balance between endocrine and exocrine cell differentiation. Diabetes 53:2322-2329, 2004 I ncreasing evidence from epidemiological studies led to the concept of the early-life origins of adult diseases, suggesting that late-onset disorders such as type 2 diabetes, glucose intolerance, or hypertension may be programmed by nutritional inadequacy in utero (1-5). Excess glucocorticoids also retard fetal growth, and overexposure to these hormones during intrauterine life has been shown to play a role in fetal programming in both humans (6) and rodents (7). The link between glucocorticoid overexposure in utero and the occurrence of metabolic diseases in adulthood has been well documented in rats. Maternal treatment with dexamethasone (DEX), a glucocorticoid agonist, induces in the offspring growth retardation at birth as well as hyperglycemia and increased systolic blood pressure at adult age (8 -10).
I
ncreasing evidence from epidemiological studies led to the concept of the early-life origins of adult diseases, suggesting that late-onset disorders such as type 2 diabetes, glucose intolerance, or hypertension may be programmed by nutritional inadequacy in utero (1) (2) (3) (4) (5) . Excess glucocorticoids also retard fetal growth, and overexposure to these hormones during intrauterine life has been shown to play a role in fetal programming in both humans (6) and rodents (7) . The link between glucocorticoid overexposure in utero and the occurrence of metabolic diseases in adulthood has been well documented in rats. Maternal treatment with dexamethasone (DEX), a glucocorticoid agonist, induces in the offspring growth retardation at birth as well as hyperglycemia and increased systolic blood pressure at adult age (8 -10) .
Similarly, inhibition of the placental 11␤-hydroxysteroid dehydrogenase type 2, the enzyme that protects the fetus from maternal glucocorticoids, induces intrauterine growth retardation as well as glucose intolerance and hypertension in adults (11) .
We have previously shown that maternal general food restriction during late pregnancy decreased the ␤-cell mass of newborn rats (12) . This reduction was irreversible and persisted in adults despite restoration of normal nutrition from weaning (13) , ultimately leading to impaired glucose tolerance associated with aging (14) or pregnancy (15) . These results sustain the notion that some of the late alterations observed in humans born with intrauterine growth retardation may result from altered ␤-cell development in utero, as initially suggested by Hales and Barker (2) . Additionally, we have recently demonstrated that maternal general food restriction in the rat induced a rise in both maternal and fetal corticosterone levels, which in turn was responsible for the decreased ␤-cell mass and islet numbers observed in the undernourished fetus (16) . These data suggested that glucocorticoids might play a role in pancreas development.
Studies of pancreatic gene expression as well as genetically modified mice have identified a large number of transcription factors that control the development of the endocrine pancreas. Several homeodomain, paired-box, and helix-loop-helix transcription factors such as Nkx6.1, Pax4, Pax6, and Ngn3 are expressed at early stages of development, and their absence leads to alterations in endocrine cell differentiation. Besides, the bHLH transcription factor Ptf1-p48, which is required for exocrine cell differentiation, and the homeodomain protein pancreas duodenum homeobox (Pdx)-1, the earliest marker of pancreatic cells and whose absence results in pancreatic agenesis, are required for the early steps of pancreas development (17) (18) (19) .
The aims of the present study were 1) to investigate whether the association between developmental injury of the ␤-cells and type 2 diabetes may be attributed to a direct effect of glucocorticoids on fetal pancreatic tissue and, if so, 2) to decipher the cellular and molecular mechanisms by which glucocorticoids could modulate pancreatic development or differentiation. We hypothesized that glucocorticoids act directly on the pancreas and that the transcription factors controlling its normal development and differentiation could be the targets of these hormones. We addressed this hypothesis by combining in vitro and in vivo approaches. First, we used a model of embryonic rat pancreas cultured in vitro in the presence of DEX to study the effect of glucocorticoids on pancreatic differentiation. We then analyzed the consequences of glucocorticoid receptor (GR) inactivation on pancreas development and organization, in mice lacking the GR either in pancreatic precursor cells (Pdx-Cre GR lox/lox mice, denominated GR Pdx-Cre thereafter) or in cells transcribing the insulin gene, whether immature or fully differentiated ␤-cells (RIP-Cre GR lox/lox mice, denominated GR RIP-Cre thereafter).
(0.1% Tween20/3% BSA in Tris-buffered saline) before a 4°C overnight incubation with primary antibodies. Cell numbers, area, and morphometrical measurements. On E15.5 rat pancreatic buds treated or not treated with DEX, cells coexpressing Pdx-1 and insulin, and cells expressing only Pdx-1 were counted on every other section throughout the bud; amylase-positive area was morphometrically measured on the other sections. A total of four control and five DEX-treated buds were analyzed. Acinar cell proliferation was studied on 3,000 -6,000 amylasepositive cells per bud.
Amylase area on E15.5 rat pancreatic buds was determined by computerassisted measurements using a DMRB microscope (Leica, Deerfield, IL) equipped with a color video camera coupled with a Q500IW computer (screen magnification, ϫ24), as previously described (13) . Pancreatic tissue area and insulin-positive or glucagon-positive cell area on adult transgenic mice were similarly measured. Briefly, the number of islets (defined as insulin-positive aggregates at least 25 m in diameter) was scored and used to calculate the islet numerical density (number of islets per square centimeter of tissue). Islets ranging from 25 to 100 m in diameter were defined as small, those ranging from 101 to 150 m as medium, and those Ͼ150 m as large. The percent ␤-cell fraction was measured as the ratio of the insulin-positive cell area to the total tissue area on the entire section. Mean ␤-cell fraction per pancreas was calculated as the ratio of the sum of insulin-positive area to the sum of pancreatic tissue area. The ␤-cell mass was obtained by multiplying the ␤-cell fraction by the weight of the pancreas. ␣-Cell fraction and mass were similarly measured. Morphometrical analysis was performed on eight sections throughout the pancreas from four GR RIP-Cre mice or six GR lox/lox and six GR Pdx-Cre mice. Statistical analysis. All results are expressed as means Ϯ SE. The statistical significance of variations was evaluated with Statview 4.5 software. Transcription factor mRNA levels were expressed as the percent of their respective control in each experiment and analyzed by a Wilcoxon's nonparametric test. Cell number, amylase cell area, cell proliferation, ␤-cell and ␣-cell fraction and mass, islet number, or repartition per size were tested by a Mann-Whitney nonparametric test. P values Ͻ0.05 were considered significant.
RESULTS
GR is expressed in pancreatic epithelial cells at E15.5. in the rat. To determine whether GR protein is present in the developing pancreas, we performed immunofluorescence on E15.5 pancreatic paraffin sections. The GR was expressed in a subpopulation of cytokeratinlabeled epithelial cells (Fig. 1A) . Because GR is already expressed in E15.5 pancreatic buds and because few cells coexpressing insulin and Pdx-1, i.e., differentiated ␤-cells, can be detected at this stage (Fig. 1B) , we further used this tissue as a model to study the effects of glucocorticoids on ␤-cell development and differentiation. DEX treatment decreases insulin-and-Pdx-1-expressing ␤-cell numbers but increases the area occupied by acinar cells. Rat pancreatic buds at E15.5 were cultured for 3 days in the presence or absence of DEX (10 Ϫ7 mol/l), a GR agonist. DEX treatment induced a small (25%) but significant decrease of total tissue area (P Ͻ 0.05). The consequences of DEX treatment on exocrine and ␤ endocrine cell differentiation were analyzed by immunohistochemistry and RT-PCR. After 3 days of culture in the absence of DEX, all cells expressing insulin coexpressed Pdx-1 and were frequently found organized into small clusters, showing that the tissue had differentiated in culture. In striking contrast, in DEX-treated buds, such ␤-cell clusters were absent and the number of cells coexpressing insulin and Pdx-1 was decreased, whereas the number of cells expressing only Pdx-1 remained unchanged ( Fig. 2A) . Concomitantly, DEX treatment led to a twofold increase of amylase-containing cells, without altering the histological organization of the acini (Fig. 2B) . Experiments of BrdU incorporation showed that acinar cell proliferation was decreased after 3 days of treatment with DEX ( Fig. 2C) but not after 1 day, at which time more amylase-expressing cells were already observed (Fig. 2D ). Taken together, these observations suggest that the increase in acinar cell area is a direct consequence of glucocorticoid-mediated stimulation of differentiation and not acinar cell proliferation. In both treated and untreated buds, ␤-cells as well as precursor cells were too few to allow any reliable quantification of their proliferation rate. DEX affects the expression levels of transcription factors involved in pancreas development. To further characterize the changes induced by glucocorticoids on E15.5 rat pancreata, we determined the mRNA levels of some of the transcription factors involved in pancreatic development and differentiation using semiquantitative duplex RT-PCR analysis (Fig. 3) . DEX treatment clearly decreased the mRNA levels of Pdx-1 (60% of the control, P Ͻ 0.05) and Nkx6.1 (50% of the control, P Ͻ 0.05). Pax6 mRNA was almost undetectable in the presence of DEX. Upon DEX treatment, no changes could be detected in either Ngn3 mRNA levels (Fig. 3) or Foxa2 and Hnf1␣ (data not shown). In striking contrast, the mRNA levels of Ptf1-p48 and Hes1, encoding transcription factors involved in exocrine cell differentiation, were increased 5-fold (P Ͻ 0.05) and 1.7-fold (P Ͻ 0.05), respectively, in the presence of DEX (Fig. 3) .
These data suggest that glucocorticoids modulate the balance of pancreatic differentiation into endocrine or exocrine cells in vitro. We next investigated whether pancreas development would be disturbed in vivo, by studying the consequences of the selective inactivation of GR in pancreatic cells. Disruption of GR in pancreatic precursor cells increases ␤-cell mass. Mice carrying the GR lox allele (21) were crossed with mice expressing the Cre recombinase either in pancreatic precursor cells (Pdx1-Cre) or specifically in cells expressing the insulin gene (rat insulin promoter, RIP-Cre). The efficiency and specificity of GR gene recombination (i.e., inactivation) were assessed by immunohistochemistry with anti-GR antibodies on pancreatic sections (Fig. 4) . In GR Pdx-Cre mice, GR staining was 
E. GESINA AND ASSOCIATES

DIABETES, VOL. 53, SEPTEMBER 2004
almost totally absent in all pancreatic cell types, although a faint labeling was sometimes detected in islets ( Fig. 4B  and E) . In GR RIP-Cre mice, the GR was specifically deleted in all differentiated ␤-cells but remained well expressed in all other pancreatic cell types, as expected ( Fig. 4C and F) . Female mice were analyzed at adult age (3-4 months) and compared with age-matched control females (Table 1) . GR deletion in ␤-cells did not alter body or pancreatic weight, but a tendency to decreased fasted glycemia was observed. GR deletion in Pdx-1-expressing cells did not alter the glycemia or the body weight but slightly increased pancreatic weight (Table 1) .
Four to six females at 3-4 months of age were used for morphometric analysis on immunostained paraffin sections. The ␤-cell fraction increased nearly twofold in GR Pdx-Cre mice (1.06 Ϯ 0.14 vs. 0.65 Ϯ 0.13% in controls, P Ͻ 0.01), in line with an increase in ␤-cell mass (2.82 Ϯ 0.36 vs. 1.50 Ϯ 0.52 mg in controls, P Ͻ 0.01) (Fig. 5) . In contrast, ␣-cell fraction and mass from GR Pdx-Cre animals were similar to those of controls (Fig. 5C ). Further characterization showed that the increased ␤-cell mass arose from increased islet numbers, mainly small and large islets (Fig. 6) , and increased area of the large islets (giant islets Ͼ300 m equivalent diameter were often observed) (Fig.  5) . Individual ␤-cell area was unchanged in GR Pdx-Cre mice (188 Ϯ 4 vs. 177 Ϯ 9 m 2 in controls, P ϭ 0.27), indicating that the ␤-cells were not hypertrophied. The increased ␤-cell fraction in GR Pdx-Cre mice was already present in neonates at 2.5 days of age (3.73 Ϯ 0.19 vs. 3.08 Ϯ 0.05% in controls, n ϭ 4 in each group, P Ͻ 0.05). A mutation restricted to ␤-cells did not have any major consequences on pancreas morphology, and GR RIP-Cre mice were similar to the control group for all parameters analyzed (Figs. 5 and 6), suggesting that glucocorticoids do not play a major role in differentiated ␤-cells.
DISCUSSION
In a previous study, we had shown that decreased ␤-cell mass was observed under conditions of fetal overexposure Data are means Ϯ SE or means Ϯ SE (P). Statistical differences between each mutant group and the control mice were assessed using the Mann-Whitney nonparametric test.
to glucocorticoids, such as that observed during fetal undernutrition, whereas large ␤-cell numbers were associated with low corticosterone levels (16) . The aim of this work was to investigate whether glucocorticoids were implicated directly in pancreatic development and to determine the cellular and molecular targets of these hormones. We hypothesized that the hormonal steroid imbalance generated by undernutrition would affect the developmental programming by modifying the balanced level of transcription factors modulating pancreas development. This hypothesis was investigated by in vitro studies of treatment with glucocorticoids and by studying mouse models lacking the GR in specific pancreatic cell populations.
In the present work, we show that in vitro treatment of the embryonic rat pancreas with DEX did not affect the number of precursor cells but decreased the number of differentiated ␤-cells and increased the differentiated acinar cell area. These results suggest that glucocorticoids decreased the differentiation of the embryonic pancreas into ␤-cells while favoring its differentiation into acinar cells. This conclusion was further sustained by the finding of decreased proliferation of amylase-expressing cells upon DEX treatment, a result suggesting that glucocorticoids could also control the proliferation of already differentiated acinar cells and thereby prevent their overgrowth. Taken together, our in vitro data suggest that the differentiation process from precursor to differentiated endocrine or exocrine cell is altered, suggesting that the precursor cells but not the differentiated ␤-cells are potential targets for glucocorticoids. Whether this in vitro situation also applies in vivo remains to be fully investigated. In line with this idea, rats undernourished during their perinatal life and thereby exposed to increased corticosterone levels in utero show increased pancreatic weight at adult age (14, 15) .
The finding that ␤-cell differentiation is impaired in glucocorticoid excess situations is reinforced in the mirror situation found in conditional mutant mice where the GR signaling is absent, such that the deletion of the GR in Pdx-1-expressing precursor cells (GR Pdx-Cre ) led to a twofold increase of ␤-cell mass, with increased islet numbers. This increased ␤-cell mass in GR Pdx-Cre animals was already observed in neonates, although to a lesser extent than in adults. Surprisingly, the decreased exocrine cell differentiation, which would have been expected from the in vitro data, was not observed in the GR Pdx-Cre mutants, since their pancreatic weight was on the contrary slightly increased. Other factors, coming either from maternal environment or adjacent tissue interactions might modulate this effect in vivo. Interestingly, while the deletion of the GR in pancreatic precursor cells led to increased ␤-cell mass, ␣-cell mass remained unaffected, indicating that glucocorticoid action was restricted to the ␤-cell lineage. On the other hand, the specific GR deletion in differentiated ␤-cells in GR RIP-Cre mice had no measurable consequences on ␤-cell or ␣-cell mass. Taken together, these findings support the idea that glucocorticoids act on undifferentiated endocrine pancreatic cells having expressed the proendocrine marker Ngn3, but before insulin gene expression onset.
During the last decade, cell lineage studies in the pancreas have shown the requirement of a group of transcription factors for normal pancreatic development (19, 24, 25) even though their chronology of action is not fully understood yet. Pdx-1 is acknowledged as the earliest, because Pdx-1-expressing cells give rise to all types of adult pancreatic cells (26, 27) before being restricted to mature ␤-cells also expressing Nkx6.1, Pax6, and other markers. Ngn3 is the common endocrine precursor cell marker (27, 28) , whereas Ptf1-p48, despite its early expression in pancreatic precursor cells (29) , is an absolute prerequisite to drive exocrine cell differentiation (30) . Moreover, Hes1 can also be considered a proexocrine transcription factor because it inhibits Ngn3 in the delta/ notch pathway (25, 31, 32) .
To further characterize the mechanisms by which glucocorticoids act on pancreas development, and hypothesizing that the hormonal steroid imbalance affects the developmental programming by modifying the level of the genes modulating pancreas development, we studied the expression of these transcription factors after in vitro treatment with DEX. Interestingly, the transcription factors implicated in ␤-cell differentiation, such as Pdx-1, Pax6, and Nkx6.1, were downregulated, whereas the exocrine-specific transcription factors Ptf1-p48 and Hes1 were upregulated upon glucocorticoid treatment. These results suggest that glucocorticoids impair ␤-cell development by favoring exocrine differentiation and that transcription factors could be their molecular targets.
The modulation of exocrine/endocrine differentiation balance had already been suggested in older in vitro studies of rat pancreatic explants treated with corticosterone, showing a decreased insulin secretion and islet mass while exocrine enzyme contents and acinar mass were enhanced (33, 34) . Additionally, the AR42J cell line, which shares some characteristics of multipotency with precursor cells, has been shown to differentiate into acinar cells when exposed to DEX (35) . The decreased Pdx-1 mRNA levels we observed are also in good agreement with similar findings obtained after treatment of mouse pancreatic buds with DEX (36) . However, the latter work argues in favor of a transdifferentiation of ␤-cells into hepatocytes without any changes in exocrine tissue. The processes involved in the two studies appear quite different. In the experiments of Shen et al. (36) , the treatment begins earlier, when more undifferentiated cells are likely to maintain a multipotency, rendering them more susceptible to de-differentiate into another tissue cell fate, whereas cells at a later stage, such as those used in our model, are more likely committed to a pancreatic cell fate.
The mechanisms by which glucocorticoids modulate the levels of the transcription factors remain to be determined. In HIT-T15 cells, it has been shown that glucocorticoids decreased the expression of Pdx-1 by inhibiting Hnf3␤ (37) . In our cultured pancreatic buds, as well as in adult rat islets (E.G., unpublished data), DEX treatment decreased Pdx-1 without inducing any changes in Hnf3␤ mRNA levels, suggesting that the mechanisms regulating Pdx-1 gene transcription could be slightly different between mature islets and ␤-cell lines. Alternatively, the transcription factor or transactivator environment could differ between precursor cells and mature ␤-cells, thereby allowing a different transcriptional control of the Pdx-1 gene. Surprisingly, the mRNA levels of the proendocrine marker Ngn3 were unaffected by in vitro DEX treatment, despite increased Hes1 mRNA levels. It is possible that the 1.6-fold increase of Hes-1 was insufficient to inhibit Ngn3; alternatively, other still unknown transcription factors controlling Ngn3 transcription could also operate, thereby interfering with the Hes-1 inhibitory effect. Further studies in the conditional GR Pdx-Cre and GR RIP-Cre mutants would help us understand how glucocorticoids affect ␤-cell lineage at the molecular level.
The present study shows that glucocorticoids are important modulators of lineage commitment in the pancreas, acting during the differentiation process rather than on mature ␤-cells. The increased islet numbers and size observed in GR Pdx-Cre mice also shows that glucocorticoids repress signals that normally control ␤-cell numbers or islet size. Despite normal ␤-cell mass in GR RIP-Cre mice, glucocorticoids could also play a role on differentiated ␤-cells or in postnatal life. Many reports have shown the importance of glucocorticoids on ␤-cell function: GLUT2 protein has been shown to be decreased (38) , glucosestimulated insulin release is also altered in adult islets treated with DEX (38 -41), and a negative glucocorticoid response element was identified on the insulin promoter (42) .
Taken together, our data show that glucocorticoids have profound effects on ␤-cell development and differentiation in vivo. Even though the molecular mechanisms by which glucocorticoids mediate their effects are only partly elucidated at this time, these results demonstrate that glucocorticoids play an important role on pancreatic ␤-cell lineage during specific developmental windows, acting before hormone gene expression onset and possibly also modulating the balance between endocrine and exocrine cell differentiation. Glucocorticoid hormones should therefore be considered as major hormones involved in normal pancreatic development. These results, together with the previously demonstrated associations of altered ␤-cell development with impaired glucose tolerance at adult age, strongly support the concept that impaired glucose homeostasis in adulthood can be programmed by glucocorticoid-induced alterations in pancreas differentiation.
